G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
June 18 2021 - 9:00AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced the appointment of Alicia Secor to its
Board of Directors. With more than 30 years of experience in the
life sciences industry, she has a proven track record of leading
life sciences businesses, guiding products from clinical
development through approval and global commercialization, and
enabling companies to optimize the potential of innovative brands.
Ms. Secor currently serves as President and Chief Executive Officer
of Atalanta Therapeutics, Inc., a privately held biotechnology
company pioneering new treatment options for neurodegenerative
diseases and is a member of its Board of Directors.
“G1 is committed to appointing new board members with strong
strategic vision and broad experience in leading life science
companies as they enhance the value of their brands, and Alicia
clearly embodies all of these traits,” said Jack Bailey, Chief
Executive Officer of G1 Therapeutics. “As a highly seasoned
executive with valuable industry experience, we look forward to
Alicia's expert advice as we seek to maximize the current and
future value of COSELA™ (trilaciclib) and ensure its broad
availability to patients with cancer. We are pleased to welcome
Alicia to our Board of Directors at this important stage of G1’s
evolution.”
“G1 has proven its ability to successfully advance innovative
products through clinical development and has established a strong
commercial capability with a focus on bringing important products
to market for patients with unmet medical needs,” said Ms. Secor.
“Few companies in the space can claim such early success. It’s an
honor to join this board to help G1 bring value to its shareholders
and develop and commercialize innovative medicines on behalf of
patients with cancer.”
Prior to her role at Atalanta Therapeutics, Ms. Secor served as
President and Chief Executive Officer of Juniper Pharmaceuticals,
Inc., a publicly traded pharmaceutical company, from August 2016
until August 2018, when the company was acquired by Catalent, Inc.
Prior to that role, Ms. Secor held various leadership positions in
the life sciences industry. From 1998 to 2013, Ms. Secor held
various roles of increasing responsibility at Genzyme (now a part
of Sanofi), culminating in her tenure as Vice President and General
Manager of Metabolic Diseases. Ms. Secor is a member of the board
of directors of Orchard Therapeutics plc, an English global gene
therapy company that is publicly traded in the United States on the
Nasdaq market, and is a board member of the Foundation for
Prader-Willi Research, a non-profit organization. Ms. Secor also
served on the board of GW Pharmaceuticals plc, a public company,
prior to its acquisition by Jazz Pharmaceuticals plc. Ms. Secor
holds an MBA from Northeastern University and earned her B.S. in
Health Administration at the University of New Hampshire.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of next generation therapies that
improve the lives of those affected by cancer, including the
Company’s first commercial product, COSELA™ (trilaciclib). G1 has a
deep clinical pipeline and is executing a tumor-agnostic
development plan evaluating COSELA in a variety of solid tumors,
including colorectal, breast, lung, and bladder cancers. G1
Therapeutics is based in Research Triangle Park, N.C. For
additional information, please visit www.g1therapeutics.com and
follow us on Twitter @G1Therapeutics.
G1 Therapeutics™ and the G1 Therapeutics logo and COSELA™ and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this press release include, but are
not limited to, those relating to the future value of COSELA
(trilaciclib) and the company’s ability to ensure broad
availability. Each of these forward-looking statements involves
risks and uncertainties. Factors that may cause the company’s
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
the company’s filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained therein
and include, but are not limited to, the company’s dependence on
the commercial success of COSELA; the development and
commercialization of new drug products is highly competitive; the
company’s ability to complete clinical trials for, obtain approvals
for and commercialize any of its product candidates; the company’s
initial success in ongoing clinical trials may not be indicative of
results obtained when these trials are completed or in later stage
trials; the inherent uncertainties associated with developing new
products or technologies and operating as a development-stage
company; and market conditions. Except as required by law, the
company assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Contact:
Will RobertsG1 Therapeutics, Inc.Vice PresidentInvestor
Relations and Corporate Communications(919) 907-1944
wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Apr 2023 to Apr 2024